StreetAlpha.app
Home › Stocks › LYEL

Lyell Immunopharma, Inc. (LYEL)

Healthcare
$13.80
▲ +1.62%
LAST CLOSE · NOV 20

Lyell Immunopharma develops engineered immune cell therapies for patients with cancer. It last closed at $13.80 on Nov 20, up 1.62% on the day. The next earnings report for LYEL is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, LYEL reported EPS of -$1.86 on revenue of $3,000, with revenue down 80.0% from a year ago. Over its last 8 reports the stock moved an average of 4.1% the session after earnings. Over the last 12 months LYEL insiders bought $75.0M of stock on the open market and sold $613K, according to SEC Form 4 filings.

AI Auto Pilots
Is LYEL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LYEL.

Key Stats

Last 12 months
Results
Revenue
$15K
−63.4% vs a year ago
Net income
−$255.2M
−1701066.7% margin
EPS (diluted)
−$12.61
Free cash flow
−$140.0M
−933100.0% margin
Valuation
Market cap
$339.3M
24.6M shares
P/E
–
No P/E while losing money
Price to sales
22618.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$92.1M
At Sep 30
Shareholder equity
$192.7M
Shares outstanding
24.6M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $10.7M$10.7MFY2021FY2022: $84.7M$84.7MFY2022FY2023: $130K$130KFY2023FY2024: $61K$61KFY2024FY2025: $36K$36KFY2025

From LYEL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 11
Estimated date · After the close
Reported EPS
-$1.86
Quarter ended Sep 2026
Year ago EPS
-$2.13
Same quarter last year
Revenue
$3,000
−80.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$14.40Dec '24Mar 2025: -$3.54Mar '25Jun 2025: -$2.89Jun '25Sep 2025: -$2.13Sep '25Dec 2025: -$7.68Dec '25Mar 2026: -$1.10Mar '26Jun 2026: -$1.92Jun '26Sep 2026: -$1.86Sep '26Latest -$1.86
Revenue by quarter
Dec 2024: $11,000Dec '24Mar 2025: $7,000Mar '25Jun 2025: $8,000Jun '25Sep 2025: $15,000Sep '25Dec 2025: $6,000Dec '25Mar 2026: $2,000Mar '26Jun 2026: $4,000Jun '26Sep 2026: $3,000Sep '26Latest $3,000
How LYEL moved after its last 8 reports
Average move the session after a report ±4.1%
Nov 4, 2026After the close−2.8%
Aug 6, 2026After the close+3.5%
May 6, 2026After the close−3.8%
Mar 12, 2026After the close−14.2%
Nov 12, 2025After the close−1.3%
Aug 12, 2025After the close+2.5%
May 13, 2025After the close−3.6%
Mar 11, 2025After the close+0.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LYELStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LYEL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LYEL

Technical Analysis

LYEL · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock is 3% above its 20 day and 20% above its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 55). The nearest support is the 20 day average at $13.41, and the nearest resistance the swing high (Jun 11) at $14.14.

Short trendBullish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 9.2%/day
Key levels
$45.0052 week high+226.1%
$16.12200 day average+16.8%
$14.30Pivot R1+3.6%
$14.14Swing high (Jun 11)+2.5%
$13.80Pivot+0.0%
$13.80Last close
$13.4120 day average−2.8%
$13.39Swing low (Aug 17)−3.0%
$13.30Pivot S1−3.6%
$12.56100 day average−9.0%
$11.0850 day average−19.7%
$7.2052 week low−47.8%
Indicators
RSI (14)55.44Middle of its rangeNeutral
MACD0.98Below its signal lineBearish
Stochastic45.3Middle of its rangeNeutral
ADX (14)36.9Trending up
Williams %R-54.2Oversold below −80, overbought above −20Neutral
CCI (20)12.7Oversold below −100, overbought above 100Neutral
Rate of change−7.1%Change over 10 sessionsBearish
ATR (14)$1.27Typical daily range, 9.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Below
What happened before, for LYEL

What happened before

See how LYEL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LYEL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LYEL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LYELHow many large options trades hit LYEL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

LYEL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲65 buying vs 32 selling
  • ▲Held by funds +0.5 pts
  • ▲Funds holding +18
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10587+20.7%
In funds' top 1047−42.9%
Held by funds52.1%51.5%+0.5 pts
New / increased28 / 3723 / 28+27.5%
Reduced / sold out22 / 1019 / 9+14.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LYEL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LYEL Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$75.0M4 buys · 4 insiders
Sold$613K28 sales · 7 insiders
Cluster buy: 2 insiders bought $50.0M between Nov 4 and Nov 4.
2025-12 sold $74K2026-02 sold $264K2026-03 bought $25.0M2026-05 sold $16K2026-06 sold $25K2026-07 sold $2742026-08 sold $205K2026-09 sold $6K2026-10 sold $4K2026-11 bought $50.0M2026-11 sold $19KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 10Lynn SeelyPresident and CEOSale545$15.93$9K
Nov 10Stephen J. HillCOOSale88$15.93$1K
Nov 10Gary K. LeeChief Scientific OfficerSale129$15.93$2K
Nov 10Veronica Sanchez BulisVP, Corporate ControllerSale416$15.93$7K
Nov 4ARCH Venture Fund XIII, L.P.10% ownerBuy2,321,262$10.77$25.0M
Nov 4ARCH Venture Partners IX, LLC10% ownerBuy2,321,262$10.77$25.0M
Every insider buy and sale for LYEL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LYEL insider trades →

From SEC Form 4 filings by LYEL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LYEL is in one of them and how their past LYEL trades turned out.

LYEL in the AI portfolios
Loading…

LYEL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LYEL in an article yet. Here's the latest on the wider market.

LYEL in the news

About Lyell Immunopharma

Lyell Immunopharma is a clinical stage biotechnology company that develops cell therapies for patients with cancer. It takes immune cells from each patient and engineers them to better find and destroy cancer cells. Its lead candidate, rondecabtagene autoleucel, is being studied in patients with large B cell lymphoma, and the company is also developing LYL273 for advanced colorectal cancer. The company is based in South San Francisco, California.

Headquarters
South San Francisco, CA